Deadpool Stack

What Is the Deadpool Stack?

The Deadpool Stack pairs three peptides that each carry a different proposed research focus. BPC-157 is a peptide originally identified in the stomach, studied for blood vessel formation and gut-related signaling. TB-500 is a fragment of Thymosin Beta-4, studied for its role in cell migration during tissue repair. Cartalax is marketed as a cartilage-specific peptide from the Khavinson bioregulator research tradition.

It's important to be direct about an asymmetry in this stack: BPC-157 and TB-500 both have identifiable, citable published research behind their individual mechanisms, even accounting for the usual caveats about animal-only data. Cartalax's own independent, peer-reviewed research base is much thinner, and much of what's claimed about it traces back to vendor marketing material rather than verifiable studies. Anyone researching this stack should weigh the three components accordingly rather than assuming equal evidence quality across all three.

What This Stack is Being Researched For?

• Tissue and Blood Vessel Support

  BPC-157's research base centers on blood vessel formation and gut-related signaling, both of which relate to how tissue receives blood flow and support.^[1][2]

• Cell Migration

  TB-500's research base centers on actin, the protein that lets cells move and change shape, making it a subject of research in wound closure and directed cell movement.^[3]

• Cartilage and Joint Tissue (as Marketed)

  Cartalax is marketed toward cartilage-specific research, proposed to support chondrocyte gene expression, though this claim rests on a much thinner and less independently verified evidence base than the other two components.

How the Stack Works

• BPC-157 and Blood Flow

  Research points to BPC-157 affecting new blood vessel formation and nitric oxide signaling, both of which relate to how well blood reaches an area of tissue.^[1][2]

• TB-500 and Cell Movement

  Research points to TB-500 interacting with actin to help direct the movement of cells like fibroblasts toward an area, a process relevant to how tissue closes and rebuilds after injury.^[3]

• Cartalax's Proposed Mechanism

  Cartalax is described in vendor sources as working through a gene-expression mechanism similar to other Khavinson bioregulator peptides, targeted at chondrocytes specifically. This mechanism has not been traced to a verifiable, independently checkable primary study.

• Why the Three Are Paired

  Since BPC-157 and TB-500's research bases center on blood flow and cell movement, and Cartalax is marketed toward cartilage specifically, researchers combining them are generally interested in addressing joint and connective tissue health from multiple angles, though the strength of that rationale depends heavily on how much weight is given to Cartalax's currently thin evidence base.

Reconstitution and Handling

All three peptides are typically supplied as a lyophilized powder in a sealed vial and reconstituted with bacteriostatic water before use in a research setting. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out for each peptide separately before mixing. Keel Bio's calculator is a commonly used tool for this. Once reconstituted, all three solutions are kept refrigerated to help preserve stability.

Key Takeaways

The Deadpool Stack pairs BPC-157 and TB-500, both with identifiable individual research bases, alongside Cartalax, whose own evidence is considerably thinner and less independently verified. Treat this stack's rationale as resting on two well-documented components and one that currently relies mostly on vendor marketing claims rather than checkable research, an important distinction to carry into how this page's claims should be weighed.

Frequently Asked Questions

Sources and Research

1. Vuksic T, Zoricic I, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768-777.
2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333.
3. Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB J. 2003;17(14):2103-2105.